GlassScriptPhysician profile
Ramamurthy N Alam
NPI 1275526352
$3,088.32
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,200 · 2020: $1,138 · 2021: $751.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $618.82 | 2019-2021 | |
| Pfizer INC. | $404.87 | 2019-2021 | |
| Novo Nordisk INC | $303.22 | 2019-2021 | |
| Glaxosmithkline, LLC. | $177.20 | 2019-2021 | |
| Horizon Therapeutics Plc | $173.32 | 2019-2021 | |
| Allergan, INC. | $164.10 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $151.68 | 2019-2021 | |
| Abbvie INC. | $138.78 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $130.44 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.49 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.15 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $84.02 | 2019-2021 | |
| Amgen INC. | $83.82 | 2019 | |
| Amarin Pharma, INC. | $79.86 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.45 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $51.01 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $38.13 | 2019 | |
| Mylan Specialty L.P. | $37.20 | 2021 | |
| Lilly USA, LLC | $36.05 | 2019 | |
| Nestle Healthcare Nutrition INC. | $18.30 | 2020 | |
| Avanir Pharmaceuticals, INC. | $17.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.50 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.36 | 2021 | |
| Vanda Pharmaceuticals INC. | $15.00 | 2019 | |
| Astellas Pharma US INC | $13.96 | 2021 | |
| Genentech USA, INC. | $13.81 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramamurthy Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.